3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
2
Sarcoma
1
Dermatologic
1
Breast
1
Conditions
Melanoma
13
Sarcoma
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Skin Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Interventions
pembrolizumab
6
cemiplimab
3
Cyclophosphamide
3
temsirolimus
2
palbociclib
2
cediranib
2
Therapeutics
2
Radiotherapy
2
Radiosurgery
2
Psychiatric Rehabilitation
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
Methods
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Gemcitabine
2
Fluorouracil
2
Drug Therapy
2
Docetaxel
2
Cisplatin
2
Capecitabine
2
Biological Therapy
2
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tanespimycin
1
sonidegib
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Injections
×
Dermatologic
×
Clear all
NCT05688280
2025-01-08
INJECTABL-1
Immunophotonics, Inc.
Phase 1/2
Active not recruiting
42 enrolled